|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Radiofrequency ablation of hepatocellular carcinoma:Current status显示文摘Ablation therapy is one of the best curative treatment options for malignant liver tumors,and can be an alternative to resection.Radiofrequency ablation(RFA) of primary and secondary liver cancers can be performed safely using percutaneous,laparoscopic,or open surgical techniques,and RFA has markedly changed the treatment strategy for small hepatocellular carcinoma(HCC).Percutaneous RFA can achieve the same overall and disease-free survival as surgical resection for patients with small HCC.The use of a laparoscopic or open approach allows repeated placements of RFA electrodes at multiple sites to ablate larger tumors.RFA combined with transcatheter arterial chemoembolization will make the treatment of larger tumors a clinically viable treatment alternative.However,an accurate evaluation of treatment response is very important to secure successful RFA therapy.Since a sufficient safety margin(at least 0.5 cm) can prevent local tumor recurrences,an accurate evaluation of treatment response is very important to secure successful RFA therapy.To minimize complications of RFA,clinicians should be familiar with the imaging features of each type of complication.Appropriate management of complications is essential for successful RFA treatment. | Yasunori Minami Masatoshi Kudo | 2010 | World Journal of Radiology2010，2，11： | 40 |
| 2 | 42,573 cases of hepatectomy in China: a multicenter retrospective investigation显示文摘Hepatectomy is currently routinely performed in most hospitals in China. China owns the largest population of liver diseases and the biggest number of liver resection cases. A nationwide multicenter retrospective investigation involving 112 hospitals was performed, and focused on liver resection for patients with hepatocellular carcinoma(HCC). 42,573 cases of hepatectomy were enrolled, and 18,275 valid cases of liver resection for HCC patients were selected for statistical analysis. The epidemiology of HCC, distribution of hepatectomy, postoperative complications and prognosis were finally analyzed. In the 18,275 HCC patients,81% had hepatitis B virus infection and 10% had hepatitis C virus infection. 38% of the HCC patients had normal Alphafetoprotein(AFP) level, and other 35% had an AFP level lower than 400 ng mL^(-1). In the study period, 97% of the hepatectomy for HCC were treated with open surgery, and 23.81% had vascular exclusion techniques. The operation time was(191.7±105.6) min,the blood loss was(546.0±562.8) m L, and blood transfusion was(543.0±1,035.2) m L. The median survival for HCC patients was 631 days, with 1-, 3-, and 5-year overall survival of 73.2%, 28.8% and 19.6%, respectively. Liver cirrhosis, multiple nodules,tumor thrombosis and high AFP level were risk factors that affect postoperative survival. | Binhao Zhang Bixiang Zhang Zhiwei Zhang Zhiyong Huang Yifa Chen Minshan Chen Ping Bie Baogang Peng Liqun Wu Zhiming Wang Bo Li Jia Fan Lunxiu Qin Ping Chen Jingfeng Liu Zhe Tang Jun Niu Xinmin Yin Deyu Li Songqing He Bin Jiang Yilei Mao Weiping Zhou Xiaoping Chen | 2018 | Science China(Life Sciences)2018，61，6： | 39 |
| 3 | 经皮射频消融与再手术治疗单个直径≤3 cm的复发性肝癌的疗效比较显示文摘目的 比较经皮射频消融(PRFA)与再手术切除治疗单个直径≤3 cm的复发性肝癌的疗效.方法 回顾性分析1999年1月至2009年12月中山大学肿瘤防治中心收治的151例复发性肝癌(单个肿瘤直径≤3 cm)患者的临床资料,其中79例患者行PRFA(PRFA组),72例行肿瘤再手术切除(再手术切除组).比较两组患者的生存率、并发症发生率及肿瘤复发情况.计量资料比较采用t检验,计数资料比较采用x^2检验,生存率计算采用寿命表法,生存曲线采用Kaplan-Meier法绘制,组间比较采用Log-rank检验.结果 PRFA组和再手术切除组并发症发生率分别为13%(10/79)和36%(26/72),两组比较,差异有统计学意义(x^2=11.411,P<0.05).PRFA组和再手术切除组1~5年累积生存率分别为89.7%、75.2%、67.1%、61.5%、56.6%和86.0%、67.6%、53.6%、44.1%、40.2%,两组总体生存曲线比较,差异无统计学意义(x^2=1.610,P>0.05).PRFA组4、5年累积生存率显著高于再手术切除组(x^2=4.682,4.196,P<0.05).PRFA组肿瘤局部复发率为5%(4/79),再手术切除组切缘复发率为3%(2/72),两组比较,差异无统计学意义(x^2=0.565,P>0.05).结论 PRFA治疗单个直径≤3 cm的复发性肝癌的长期疗效优于再手术切除,且具有微创的优势. | 梁惠宏 彭振维 陈敏山 邵子力 彭和平 张耀军 张亚奇 李锦清 | 2011 | 中华消化外科杂志2011，10，1： | 27 |
| 4 | Risk factors for early recurrence of small hepatocellular carcinoma after curative resection显示文摘BACKGROUND:Poorer prognosis is seen in patients with hepatocellular carcinoma (HCC) after curative hepatic resection with early recurrence (≤1 year) than in those with late recurrence (>1 year).This study aimed to identify risk factors for postoperative early recurrence of small HCC (≤3 cm in diameter).METHODS:The study population consisted of 158 patients who underwent curative resection for small HCC between January 2002 and July 2004.Risk factors for early recurrence were analyzed.RESULTS:Thirty-three (20.8%) patients developed early recurrence after surgery.Univariate analysis showed the following significant risk factors for early recurrence in small HCC:serum alpha-fetoprotein (AFP) level >100 ng/ml,lack of tumor capsule formation,microscopic vascular invasion,high Edmonson-Steiner grades,and cytokeratin-19 (CK-19) expression (P<0.05).Multivariate stepwise logistic regression analysis showed that serum AFP level >100 ng/ml (odds ratio 2.561,95% confidence interval 1.057 to 6.206,P=0.037) and microscopic vascular invasion (odds ratio 4.549,95% confidence interval 1.865 to 11.097,P=0.001) were independent factors.CONCLUSIONS:Postoperative early recurrence is related to serum AFP level >100 ng/ml and microscopic vascular invasion in patients with small HCC.Adjuvant therapy and careful follow-up are required for patients with these risk factors. | Zhou, Yan-Ming Yang, Jia-Mei Li, Bin Yin, Zheng-Feng Xu, Feng Wang, Bin Xu, Wen Kan, Tong | 2010 | Hepatobiliary & Pancreatic Diseases International2010，9，1： | 24 |
| 5 | 预知子种子提取物抑制HepG2肝癌细胞的增殖及黏附作用及相关机制显示文摘目的:观察预知子种子提取物抑制HepG2肝癌细胞的增殖及黏附作用,探讨其相关机制。方法:将中药预知子种子醇提物(1. 5,1. 8,2. 1,2. 4,2. 7,3. 0 g·L-1)和整合素抑制剂西仑吉肽(Cilengitide)(0. 5,1. 0,2. 0,4. 0,8. 0,32μmol·L-1)作用于HepG2肝癌细胞,噻唑蓝(MTT)比色法获得各药物作用24 h后的细胞存活率检测结果,并依据该结果设置组别和用药浓度,中药组(预知子醇提物1. 8 g·L-1),Cilengitide组(Cilengitide,1. 5μmol·L-1),半量联合用药组(0. 9 g·L-1+0. 75μmol·L-1),作用24 h后观察对细胞-基质黏附能力的影响,以及相关黏附分子蛋白相对表达量的变化。结果:MTT实验结果显示,不同药物处理HepG2细胞24 h后,中药1. 8 g·L-1组细胞黏附率在86. 8%左右,Cilengitide1. 5μmol·L-1组细胞存活率在89. 4%左右。细胞-基质黏附实验中,空白组细胞-基质黏附率为(100. 0±11. 5)%,中药组为(32. 3±14. 0)%,Cilengitide组为(33. 8±5. 7)%,半量联合用药组为(33. 4±6. 4)%,各用药组细胞存活率显著低于空白组(P <0. 01)。与空白组比较,中药组小亚基钙蛋白酶1(CAPNS1),硒蛋白P(SEPP1)和整合素α2(ITGA2)蛋白的表达量均上升(P <0. 05);Cilengitide组SEPP1蛋白表达量上升(P <0. 05),整合素αV(ITGAV)蛋白的表达量下降(P <0. 01);半量联合组CAPNS1,SEPP1蛋白表达量均上升(P <0. 05),ITGAV蛋白表达量下降(P <0. 05)。结论:预知子种子醇提物能抑制HepG2肝癌细胞的增殖及黏附作用;和Cilengitide联合用药后存在减量增效潜能;以上黏附分子蛋白表达量的变化,可能是预知子的部分作用机制。 | 宋秋佳 卢文丽 方肇勤 潘志强 | 2018 | 中国实验方剂学杂志2018，24，24： | 18 |
| 6 | β-榄香烯抗肝癌的促凋亡机制研究显示文摘目的:研究中药莪术提取物β-榄香烯对人肝癌HepG2细胞增殖抑制及诱导凋亡,以及小鼠肝癌H22荷瘤小鼠凋亡相关蛋白表达的作用。方法:体外培养人肝癌HepG2细胞,MTT法检测β-榄香烯对细胞增殖的影响,Annexin V-FITC/PI双染检测细胞凋亡。通过建立H22小鼠肝癌荷瘤模型,观察β-榄香烯对荷瘤小鼠肿瘤生长的抑制作用及凋亡相关蛋白的表达。结果:β-榄香烯对HepG2细胞具有抑制增殖的作用,呈剂量和时间的依赖性;Annexin V-FITC/PI法检测到早期凋亡细胞。不同实验组对荷瘤小鼠肿瘤生长的抑制作用程度不同,各药物浓度组Caspase-3蛋白均上调(P<0.05),P65蛋白均下调。结论:β-榄香烯可有效抑制人肝癌HepG2细胞的增殖,其抑制癌细胞增殖的途径是通过诱导细胞发生凋亡,并且与上调凋亡相关蛋白Caspase-3、下调NF-κB P65相关。 | 欧阳俊 沈洪 刘军楼 刘亚军 谷静 | 2014 | 世界科学技术-中医药现代化2014，16，4： | 16 |
| 7 | 血清AFP、CEA、CA19-9和CA125检测在原发性和转移性肝细胞癌诊断中的临床价值显示文摘分别检测33例原发性肝细胞癌(PHC)和19例转移性肝细胞癌(MHC)患者外周血血清中肿瘤标志物甲胎蛋白(AFP)、癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、肿瘤抗原125(CA125)水平,并对2组患者的检测结果进行比较。PHC和MHC患者相比,血清AFP、CEA和CA19-9阳性率有统计学差异(P<0.05)。检测患者血清肿瘤标志物AFP和CEA对于诊断PHC和MHC具有一定的临床参考价值。 | 翁洋 王吉魁 温艳惠 矫树华 | 2016 | 中国医科大学学报2016，45，5： | 16 |
| 8 | Impact of antiviral therapy on post-hepatectomy outcome for hepatitis B-related hepatocellular carcinoma显示文摘The outcome after curative resection for hepatocellular carcinoma(HCC)remains unsatisfactory due to the high recurrence rate after surgery.In patients with hepatitis B virus(HBV)-related HCC,which is the majority of patients with HCC in Asia,a high viral load is a strong risk factor for HCC recurrence.It is logical to believe that antiviral therapy may improve the postoperative outcome by promoting viral clearance and hepatocyte regeneration,as well as improving residual liver volume in HCC patients with hepatitis B.However,the effect of antiviral therapy on clinical outcomes after liver resection in patients with HBV-related HCC remains to be established.There are two main groups of antiviral treatment for HBV-oral nucleos(t)ide analogues and interferon.Interferon treatment reduces the overall incidence of HBV-related HCC in sustained re-sponders.However,side effects may limit its long-term clinical application.Nucleos(t)ide analogues carry fewer side effects and are potent in terms of viral suppression when compared to interferon and are typically implemented for patients with more advanced liver diseases.They may also improve the outcome after curative resection for HBV-related HCC.There are increasing evidence to suggest that antiviral therapy could suppress HBV,decrease the perioperative reactivation of viral replication,reduce liver injury,preserve the liver function before and after operation,and may lower the risk of HCC recurrence.After all,antiviral therapy may improve the survival after liver resection by reducing recurrence and delaying the liver damage by the virus,resulting in a higher chance of receiving aggressive salvage therapy during HCC recurrence. | Charing Ching Ning Chong Grace Lai Hung Wong Paul Bo San Lai | 2014 | World Journal of Gastroenterology2014，20，20： | 15 |
| 9 | 普美显在肝脏疾病诊断中的应用现状显示文摘影像学检查技术对于肝脏疾病的诊断占据很重要的地位,其中又以CT和MRI最有实用价值,现已成为临床肝脏疾病诊断与鉴别诊断的常规检查方法。MRI因为具有良好的组织对比性并且由于多种造影剂的使用,使得其在肝脏疾病诊断中的应用价值越来越高,笔者就MRI的特异性造影剂普美显在肝脏疾病诊断中的应用进行综述。 | 黄利利 李梅 程志斌 | 2013 | 中国普通外科杂志2013，22，7： | 15 |
| 10 | 超声造影在肝动脉化疗栓塞术联合微波消融治疗肝癌效果评估中的应用显示文摘目的通过对比研究超声造影(CEUS)与多层螺旋CT(MDCT)在肝癌行肝动脉化疗栓塞术(TACE)联合微波消融后的影像,探讨超声造影在肝癌TACE后效果评估中临床价值.方法对82例肝癌患者行TACE联合微波消融术进行治疗,术后4周及24周分别行CEUS及MDCT检查,将检查结果与病理确诊结果进行比较分析.结果术后4周CEUS的评价敏感性为100%,准确率为69.5%;MDCT敏感性为78.1%,准确率为91.5%.术后24周CEUS的评价敏感性为100%,准确率为97.7%;MDCT敏感性为100%,准确率为97.1%.结论与MDCT相比,CEUS可在术后较短时间内及时发现复发病灶,有利于及时进行针对性治疗. | 王海军 程瑞洪 王朝晖 王春燕 | 2017 | 北华大学学报(自然科学版)2017，18，5： | 15 |
| 11 | 原发性肝癌的发生机制及中西医治疗研究进展显示文摘原发性肝癌是我国乃至世界上最常见、最具有危害性的恶性肿瘤之一。世界卫生组织国际癌症研究署发布的2015年全球癌症报告显示,全球肝癌死亡人数约为75.1万,我国每年约有38.3万人死于肝癌,占全球肝癌死亡总数的51%[1]。近年来肝癌发病率和死亡率呈上升趋势,严重威胁人类生命健康[2]。目前,肝癌的5年生存率大约为14%[3];由于起病隐匿,肝癌被发现时多处于中晚期,并且大部分常合并肝硬化,同时伴有肝功能异常,此时手术治疗或化学栓塞不再可行,多采用姑息治疗方式。在姑息治疗中,中西医结合治疗具有重要作用。中药可减轻肿瘤患者临床症状和体征,提高机体免疫功能,改善生活质量,实现对放、化疗的减毒增效,并减少细胞耐药的出现,实现“带瘤生存”[4]。现本文对原发性肝癌病因、发病机制及中西医治疗研究进展综述如下。 | 王雅欢 黄晓桃 吴云霞 | 2019 | 中西医结合研究2019，11，3： | 15 |
| 12 | 肝癌微创介入治疗显示文摘肝癌是全球第七常见的癌症,全球每年的新发病例约748000例,是全球癌症相关死亡的第三大原因。肝癌亦是我国癌症中的第2号杀手,全球50%以上的肝癌发生在我国。罹患肝癌的高危人群以35~65岁的中年人为主,尤其以男性居多,比率为女性的2~4倍。高达80%的肝癌患者同时患有肝硬化。HBV、HCV感染是最主要的病因(约80%),其次是酒精、药物、摄食含有黄曲霉毒素的食物等。肝癌是高侵袭性的恶性肿瘤,早期症状不明显,导致大多数患者就诊较晚。这些患者大部分都是家庭经济支柱,因此,肝癌对个人、家庭及社会可造成较大影响,有效地预防、及早诊断和有效治疗肝癌十分重要[1]。 | 刘允怡 赖俊雄 | 2020 | 中华肝脏外科手术学电子杂志2020，9，3： | 15 |
| 13 | 原发性肝癌术后复发与转移的非手术治疗现状与进展显示文摘原发性肝癌术后死亡的主要原因为复发与转移,肝癌根治性切除术后复发转移率高,大多数原发性肝癌术后复发转移的患者无法行二次切除术,临床上目前尚无特异性防治措施,非手术治疗显得尤为重要。包括放疗、化疗、局部消融、免疫靶向、中医中药等在内的非手术治疗方法单独或联合应用于原发性肝癌术后复发与转移的防治,在临床具有重要的作用。 | 杨林 秦建民 | 2011 | 肝胆胰外科杂志2011，23，2： | 14 |
| 14 | 肝癌侵袭转移的中医药研究进展显示文摘肝癌是一种常见的恶性肿瘤,其发病率和死亡率高居不下。肝癌的侵袭和转移是影响肝癌患者治疗效果的重要因素,也是评估患者预后和生存期的有效指标之一。因此,抑制肝癌细胞侵袭和转移已成为肝癌治疗的研究热点。本文从肝癌侵袭转移的中医药理论研究、实验研究及临床研究三个方面进行总结,对肝癌侵袭转移的中医药研究进展进行综述。 | 张颖 周媛凤 胡敏 | 2017 | 中国临床药理学与治疗学2017，22，5： | 13 |
| 15 | Health-related quality of life evaluated by tumor node metastasis staging system in patients with hepatocellular carcinoma显示文摘AIM: To investigate and evaluate the change in healthrelated quality of life (HRQoL) by tumor node metastasis (TNM) staging system in patients with hepatocellular carcinoma (HCC). METHODS: A total of 140 patients diagnosed with HCC between June 2008 and April 2009 in our department were enrolled to this study. One hundred and thirty-five (96.5%) patients had liver cirrhosis secondary to hepatitis B virus (HBV) infection, 73 (54.07%) of them being HBV DNA positive; the other etiologies of liver cirrhosis were alcoholic liver disease (1.4%), hepatitis C (1.4%) or cryptogenic (0.7%). All subjects were fully aware of their diagnosis and provided informed consent. HRQoL was assessed before treatment using the functional assessment of cancer therapy-hepatobiliary (FACT-Hep) questionnaire. Descriptive statistics were used to evaluate demographics and disease-specific characteristics of the patients. One-way analysis of variance and independent samples t tests were used to compare the overall FACT-Hep scores and clinically distinct TNM stages. Scores for all FACT-Hep items were analyzed by frequency analyses. The mean scores obtained from the FACT-Hep in different Child-Pugh classes were also evaluated. RESULTS: The mean FACT-Hep scores were reduced significantly from TNM StageⅠto Stage Ⅱ, Stage ⅢA, Stage ⅢB group (687 ± 39.69 vs 547 ± 42.57 vs 387 ± 51.24 vs 177 ± 71.44, P = 0.001). Regarding the physical and emotional well-being subscales, scores decreased gradually from Stage Ⅰ to Stage ⅢB (P = 0.002 vs Stage Ⅰ; P = 0.032 vs Stage Ⅱ; P = 0.033 vs Stage ⅢA). Mean FACT-Hep scores varied by Child-Pugh class, especially in the subscales of physical well-being, functional well-being and the hepatobiliary cancer (P = 0.001 vs Stage I; P = 0.036 vs Stage Ⅱ; P = 0.032 vs Stage ⅢA). For the social and family well-being subscale, only Stage ⅢB scores were significantly lower as compared with Stage Ⅰ scores (P = 0.035). For the subscales of functional well-being and hepatobiliary cancer, there were significant differences for Stages ⅡΙ, ⅢA and ⅢB (P = 0.002vs StageⅠ). CONCLUSION: HRQoL of patients with HCC worsens gradually with progression of TNM stages. The most impaired subscales of HRQoL, as measured by FACT-Hep, were physical and emotional well-being. | Cui-Xia Qiao Xiao-Feng Zhai Chang-Quan Ling Qing-Bo Lang Hui-Juan Dong Qun Liu Mou-Duo Li | 2012 | World Journal of Gastroenterology2012，18，21： | 11 |
| 16 | 肝癌发生侵袭与转移分子机制的研究进展显示文摘肝细胞癌(hepatocellular carcinoma,HCC)在我国为常见的恶性肿瘤。侵袭与转移是肝癌重要的生物学特征,转移和复发是引起肝癌患者死亡的主要因素。肝癌一旦发生转移则明显影响预后。因此,控制肝癌细胞侵袭和转移对于降低肝癌死亡率具有重要意义。本文就近年有关肝癌在侵袭与转移过程中涉及到的生化标志物等研究进展作一综述。 | 郭燕 刘文超 | 2014 | 现代肿瘤医学2014，22，4： | 10 |
| 17 | 微波消融治疗肝脏恶性肿瘤的临床价值显示文摘目的:探讨微波消融(MWA)治疗肝脏恶性肿瘤的临床疗效及并发症分析。方法:208例肝脏恶性肿瘤患者接受了241例次的MWA。肝细胞肝癌(HCC)171例行198例次的MWA,肿瘤总数301个,平均1.5个,肿瘤平均最大直径(2.9±1.3)em,其中57例接受了肝切除联合MWA;肝转移癌(MLC)37例行43例次的MWA,肿瘤总数67个,平均1.6个,肿瘤平均最大直径(2.6±1.5)cm。全组病例的治疗通过经皮和开腹两种途径,治疗后定期进行影像学和肿瘤标志物检查。结果:MWA 1个月后行增强CT检查,HCC 301个肿瘤中285个完全消融,完全消融率为94.7%(285/301),MLC 67个肿瘤中62个完全消融,完全消融率为92.5%(62/67)。随访3~43个月,HCC局部复发率为8.4%(24/285),1、2、3年生存率分别为89.0%、74.2%、53.6%,其中肝切除联合MWA治疗的患者1、2、3年生存率分别为81.3%、66.4%、46.7%;MLC局部复发率为9.7%(6/62),中位生存期17~23个月。HCC患者MWA的严重并发症发生率为2.5%(5/198),MLC患者的治疗未出现严重并发症。结论:MWA治疗肝脏恶性肿瘤创伤小,安全有效,具有重要的临床价值。 | 袁强 王毅军 经翔 丁建民 杜智 | 2012 | 中国肿瘤临床2012，29，15： | 10 |
| 18 | 经肝动脉化疗栓塞术治疗中晚期肝癌的预后因素分析显示文摘目的分析影响TACE治疗中晚期肝癌生存期的因素。方法回顾性分析67例中晚期肝癌接受TACE术患者的临床资料,采用Kaplan-Meier及Log-rank分析影响预后的因素,Cox比例风险回归模型进行多因素分析。结果全组患者中位生存期12个月(95%CI:7.82,16.17),1、2、3年生存率分别为44.78%(30/67)、13.43%(9/67)和5.97%(4/67)。单因素预后分析显示:既往有无射频治疗、有无动静脉瘘、BCLC分期、有无门静脉癌栓、ECOG评分、远处转移、ALT、后继索拉菲尼治疗情况与中晚期肝癌患者的预后有关(P<0.05);多因素预后分析显示远处转移及门静脉癌栓与中晚期肝癌患者预后有关(B>0,P<0.05)。结论合并远处转移及门脉癌栓是中晚期肝癌患者预后的独立影响因素。 | 余梁 吕维富 | 2015 | 中国介入影像与治疗学2015，12，1： | 10 |
| 19 | 抗肝癌干细胞功能性单克隆抗体的研制显示文摘目的:研制抗肝癌干细胞的功能性单克隆抗体,为肝癌干细胞的靶向治疗提供候选抗体药物。方法:从人肝癌组织中分离人肝癌干细胞样细胞(human liver cancerstem-like cells,hLCSLCs),免疫BALB/c裸鼠,采用脾细胞融合法制备大容量单抗库。应用细胞免疫荧光、无血清成球培养、裸鼠皮下成瘤等方法筛选、鉴定特异识别肝癌干细胞的单克隆抗体。流式细胞仪分选hLCSLCs侧群细胞(hLCSLCs side population cells,hLCSLCs-SP),无血清悬浮培养法和CCK-8法检测杂交瘤单抗对hLCSLC-SP自我更新和增殖能力的影响。结果:细胞融合后获得2964株杂交瘤克隆,在能与hLCSLCs反应的237株克隆中,有116株单抗能与hLCSLCs的细胞膜结合,其中的33株杂交瘤单抗只与hLCSLC-SP反应(阳性率为2%~5%)、不与非hLCSLC-SP反应。该33株单抗中有6株能与CD133阳性细胞有不同比例的共染,并且与无血清悬浮培养的成球细胞呈阳性反应(阳性率为3%~26%),明显高于hLCSLCs-SP。裸鼠皮下接种1×104个15D2单抗阳性的hLCSLCs,成瘤率为100%。功能性筛选实验发现,6株单抗中的4株能显著抑制hLCSLC-SP的增殖和成球生长,其抑制率分别为24%~42%和13%~50%。结论:采用自建的大容量单克隆抗体库技术,筛选获得了4株特异性识别hLCSLC-SP的功能性单抗,为肝癌干细胞的抗体靶向治疗奠定了基础。 | 孙力超 赵璇 遇珑 韩璐璐 刘彤 胡海 孙立新 杨治华 冉宇靓 | 2010 | 中国肿瘤生物治疗杂志2010，17，2： | 10 |
| 20 | 复发性肝癌治疗的研究进展与展望显示文摘肝癌治疗后复发是影响肝癌患者长期生存的瓶颈,探索复发性肝癌的切实有效临床干预策略是提高患者远期生存率的关键,目前认为,肝切除术和肝移植术仍是复发性肝癌的最佳治疗方法,对于不能手术切除的肝癌复发患者,局部消融、靶向治疗及中医药治疗等治疗措施是延长患者生存的有效方法。对于复发性肝癌的治疗,重视复发的危险因素,加强术后随访,早期发现、早期诊断及选择合适的治疗方法才是获得最佳疗效的有效途径。 | 刘城林 梁昆 于礼建 | 2018 | 世界最新医学信息文摘2018，18，84： | 10 |
您所在的机构暂未开通此部分的功能，请联系管理员